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Abstract
Background: Intra-articular injection of monosodium iodoacetate (MIA) in the knee joint of rats disrupts
chondrocyte metabolism resulting in cartilage degeneration and subsequent nociceptive behavior that has been
described as a model of osteoarthritis (OA) pain. Central sensitization through activation of mitogen activated
protein kinases (MAPKs) is recognized as a pathogenic mechanism in chronic pain. In the present studies, induction
of central sensitization as indicated by spinal dorsal horn MAPK activation, specifically ERK and p38
phosphorylation, was assessed in the MIA-OA model.
Results: Behaviorally, MIA-injected rats displayed reduced hind limb grip force 1, 2, and 3 weeks post-MIA
treatment. In the same animals, activation of phospho ERK1/2 was gradually increased, reaching a significant level
at post injection week 3. Conversely, phosphorylation of p38 MAPK was enhanced maximally at post injection
week 1 and decreased, but remained elevated, thereafter. Double labeling from 3-wk MIA rats demonstrated spinal
pERK1/2 expression in neurons, but not glia. In contrast, p-p38 was expressed by microglia and a subpopulation of
neurons, but not astrocytes. Additionally, there was increased ipsilateral expression of microglia, but not astrocytes,
in 3-wk MIA-OA rats. Consistent with increased MAPK immunoreactivity in the contralateral dorsal horn, mechanical
allodynia to the contralateral hind-limb was observed 3-wk following MIA. Finally, intrathecal injection of the MEK1
inhibitor PD98059 blocked both reduced hind-limb grip force and pERK1/2 induction in MIA-OA rats.
Conclusion: Results of these studies support the role of MAPK activation in the progression and maintenance of
central sensitization in the MIA-OA experimental pain model.
Background
Osteoarthritis (OA), recognized as the most common
form of degenerative arthritis, is caused by progressive
disintegration of articular cartilage, bony overgrowth at
the joint margins and synovial proliferation that can
result in loss of joint function, disability and chronic
pain [1-3]. The use of preclinical pain models to exam-
ine the pathogenic mechanisms responsible for OA-
induced pain are being utilized for developing more
effective therapeutic intervention [4,5]. A commonly
used chemical model of OA pain involves intra-articular
injection of the metabolic inhibitor monosodium iodoa-
cetate (MIA) in the hind limb knee joint of rats, which
disrupts chondrocyte glycolysis through inhibition of
glyceraldehyde-3-phosphate dehydrogenase, leading to
eventual cell death [6,7]. The progressive loss of chon-
drocytes following MIA results in histological and
morphological changes of the articular cartilage similar
to the pathology observed in OA patients [8-10]. In addi-
tion, focal bone damage observed with intra-articular MIA
injection in rat has been reported to produce peripheral
nerve injury as demonstrated by increased expression of
the nerve injury marker ATF-3 (activating transcription
factor-3) in L5 dorsal root ganglia, consistent with patho-
genic changes associated with neuropathic pain [11]. * Correspondence: younglim.lee@abbott.com
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any medium, provided the original work is properly cited.However, analysis of pain behaviors such as weight bear-
ing, tactile allodynia and mechanical hyperalgesia in the
MIA-OA model have only recently been established, rais-
ing questions as to the appropriate behavioral endpoints
for evaluating mechanisms and efficacy of novel analgesics
for treating OA [4,7,12,13]. Determining biochemical sig-
naling changes associated with nociceptive behaviors in
MIA-injected animals may provide an alternative index of
nociception, as well as improved understanding of cellular
mechanisms involved in this model of OA pathology.
It has been demonstrated that during the first week
following MIA injection, transient synovial inflammation
may be the underlying cause of pain, whereas pain sen-
sation in later stages may be due to biomechanical
changes affecting the articular cartilage and subchondral
bone [7]. Joint inflammation surrounding terminal end-
ings of primary afferent neurons can be sensitized and
activated by both normally innocuous and non-painful
stimuli (peripheral sensitization) [14,15]. In turn, neu-
rons in the spinal cord also become more responsive to
innocuous and noxious stimuli onto the inflamed joint
as well as adjacent non-inflamed normal tissue (central
sensitization) [15,16]. Together, cellular sensitization in
both peripheral and central sensory neurons is believed
to be key in the initiation and maintenance of nocicep-
tive transmission in chronic pain [17].
The causes leading to central sensitization of pain can
be many-fold. It is known that primary afferent neurons
release more transmitters upon stimulation following
peripheral sensitization (presynaptic component), and
neurons in the spinal cord are more excitable due to
changes in receptor sensitivity (post synaptic component)
[15]. One possible underling mechanisms for enhanced
post synaptic sensitivity is up-regulation of second mes-
senger system activation upon stimulation. Among var-
ious second messenger systems associated with pain
responses, the family of mitogen-activated protein
kinases (MAPKs) is likely candidates for development
and maintenance of central pain sensitization. The
MAPKs are serine/threonine protein kinases that include
extracellular signal-regulated protein kinase (ERK) and
p38 [18,19]. In the present study, we investigated the
involvement of ERK1/2 and p38 phosphorylation-activa-
tion as an index of pain-induced central sensitization in
the rat MIA model of osteoarthritis. Evaluating the tem-
poral and activation profile of ERK1/2 and p38 may pro-
vide better understanding of disease progression in OA
and the role of the MAPKs in development and mainte-
nance of pain-induced central sensitization.
Results
MIA-induced pain behavior
Movement-induced pain behavior was measured using
hind limb compressive grip force evaluation in which
rats exhibit pain behaviors epitomized by a long-lasting
decrement in bilateral compressive hind limb grip force
following MIA-induced unilateral knee injury, as pre-
viously described [13]. Hind limb grip force was signifi-
cantly reduced 1, 2, and 3 weeks following MIA
injection into the hind-limb knee joint (Figure 1). At
each time point, a similar reduction (~ 55%) in grip
force was observed in all three OA groups as compared
to non-pain controls (ANOVA; f = 101.7, p < 0.0001).
MIA-induced pERK1/2 immunoreactivity
Spinal cords were harvested (immediately following grip
force testing) and immunohistochemically evaluated for
changes in MAPK phosphorylation-activation at 1, 2, and
3-wk following intra-articular MIA injection. A significant
overall increase in spinal pERK1/2 expression was observed
in MIA-OA rats (ANOVA: F = 2.965, p = 0.0134), illu-
strated in Figure 2. Specifically, increased phospho-ERK1/2
immunoreactivity (black stained cells) was primarily
observed in the upper lamina of the ipsilateral dorsal horn
(Figure 2B) that reached maximal levels at 3-wks as com-
pared to naive (non-pain) controls (Figure 2A). Similarly, a
time-dependent increase in pERK1/2 expression was
observed in the contralateral dorsal horn reaching maximal
levels in the 3-wk MIA-OA group, albeit to a lesser extent
in comparison to the ipsilateral side.
MIA-induced changes in p38 MAPK immunoreactivity
MIA-treated rats also displayed a significant increase in
p38 phosphorylation-activation in the ipsilateral spinal
dorsal horn (Figure 3). However, in contrast to pERK,
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Figure 1 Hind limb grip force following MIA knee injection in
rat. MIA injection significantly decreased grip force 1, 2, and 3 wk
post MIA injection. One-way ANOVA showed a significant treatment
effect (F = 101.7, p < 0.0001); post-hoc analysis (Fisher’s PLSD)
revealed a significant grip force deficit in the 1, 2, and 3 wk-post
MIA groups. Grip force strength was expressed as CFmax/kg body
weight and represented as mean values (± S.E.M); ** p < 0.01 vs.
naïve controls; n = 6/group.
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Page 2 of 10p38 phosphorylation was maximal at post injection week
1 and reduced thereafter (2 and 3 wk), although p-p38
expression remained significantly elevated compared to
naïve controls at each time point (Figure 3A). Cellular
phospho-p38 immunoreactivity (black stained cells) was
observed throughout the dorsal horn lamina (Figure 3B).
Similar to ERK, increased p-38 phosphorylation was
observed in the contralateral dorsal horn, but to a lesser
magnitude in comparison to ipsilateral side that was
maximal in the 1-wk group and subsequently declining
at 2 and 3 wk following MIA.
Cellular phenotype of spinal pERK1/2 and p-p38
expressing cells in MIA-OA rats
To determine the cellular phenotype of pERK1/2 and p-
p38 expressing cells in the dorsal horn spinal cord of
MIA-OA rats, double labeling experiments were con-
ducted with the neuronal, astroglia, and microglia antibo-
dies anti-NeuN, anti-GFAP and anti-OX-42, respectively
(Figure 4). Three weeks following MIA injection, ERK1/
2 phosphorylation was observed in dorsal horn neurons
as evidenced by the colocalization of anti-pERK1/2 and
anti-NeuN immunoreactivity (Figure 4A). In contrast,
pERK1/2 expression was not observed in either astro-
cytes (Figure 4B) or microglia( F i g u r e4 C ) .C o n v e r s e l y ,
p38 phosphorylation in the spinal dorsal horn was
observed in microglia (Figure 4F), but not astrocytes
(Figure 4E). In addition, spinal p-p38 expression was
also observed in a subpopulation of small-diameter neu-
rons (Figure 4D), in particular at the level of the super-
ficial lamina (1-2).
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Figure 2 ERK phosphorylation following MIA injection.E R K 1 / 2
phosphorylation was increased in both ipsilateral and contralateral
dorsal horn spinal cord at 2 and 3 wk following MIA compared to
naïve control rats, (A). Phospho-ERK1/2 immunoreactivity (black
stained cells) was observed in the upper lamina (hatched box) of
the dorsal horn (B) that reached maximal levels at 3-wks as
compared to naive (non-pain) controls. An overall ANOVA showed a
significant main treatment effect (F = 2.965, p = 0.0134). All data are
represented as mean values (± S.E.M) of the percent of ipsilateral
naïve control rats; * p < 0.05, ** p < 0.01, vs. naïve controls (Fisher’s
PLSD post hoc analysis); n = 6/group.
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Figure 3 P38 phosphorylation following MIA injection.P 3 8
phosphorylation was increased in both ipsilateral and contralateral
dorsal horn spinal cord at 1, 2 and 3 wk following MIA as compared
to naïve control rats (A). Phospho-p38 immunoreactivity (black
stained cells) was observed throughout the upper lamina (hatched
box) of the dorsal horn (B) that reached maximal levels at 1-wk and
declined thereafter as compared to naive (non-pain) controls
(ANOVA: F = 9.686, p < 0.0001). All data are represented as mean
values (± S.E.M) of the percent of ipsilateral naïve control rats; * p <
0.05, ** p < 0.01 vs. naïve controls (Fisher’s PLSD post hoc analysis);
n = 5-7/group.
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Page 3 of 10MIA-induced changes in OX-42 microglia and GFAP
astroglia immunoreactivity
In addition to MAPK expression, spinal microglia acti-
vation was examined in OA rats 3-wk following MIA
injection (Figure 5). Increased expression of the micro-
glia cell surface marker CD11b was observed in the ipsi-
lateral, but not contralateral, dorsal horn 3-wk following
MIA knee injection as compared to naïve (non pain)
controls, as measured by OX-42 immunoreactivity
(Figure 5A). In contrast, there was no change in ipsilateral
(or contralateral) astroglia expression in the dorsal horn
3-wk following MIA injection as compared to controls, as
measured by GFAP immunoreactivity (Figure 5B).
MIA-induced changes in pERK1/2 and mechanical
allodynia nociceptive testing
To test whether increased MAPK activation observed in
the contralateral (to MIA injection) dorsal horn translated
to a nociceptive phenotype, mechanical allodynia was
assessed on the contralateral paw 3-wk following MIA
injection, as measuring grip force does not allow beha-
vioral differentiation between the contra and ipsilateral
paw (Figure 6). Withdrawal threshold was significantly
reduced (mechanical allodynia) in the contralateral paw
3-wk following MIA as compared to naïve control rats
(Figure 6A), a time when reduced grip strength is consis-
tently observed [13]. In the same animals, elevated ERK1/2
phosphorylation was evident in both the ipsilateral and
contralateral dorsal horn (Figure 6B). The elevated pERK
and mechanical allodynia observed in the contralateral
spinal dorsal horn and paw, respectively, of MIA-OA rats
supports biochemical translation to a nociceptive
phenotype.
MEK1 inhibitor, PD98059, on MIA-induced pain behavior
and pERK1/2 expression
To examine the functional role of spinal pERK in med-
iating nociceptive behavior, the MEK (ERK1/2 kinase)
inhibitor PD98059 was tested in 3-wk MIA-OA rats.
Intrathecal (i.t.) administration of PD98059 30-min
before nociceptive behavior assessment significantly
attenuated the MIA-induced reduction of grip force
strength (Figure 7A). As expected, MIA-OA vehicle-i.t.
controls rats displayed a significant increase in spinal
NeuN
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Figure 4 Expression of spinal pERK1/2 and p-p38 in neuronal and glial cells of MIA-OA rats. Immunohistochemical double-labeling with
the fluorescence dyes Cy2 (red; pERK1.2 or p-p38) and Cy3 (green; NeuN, GFAP, or OX-42) was conducted in lumbar spinal cord sections where
orange-yellow fluorescence represents colocalization (white arrow). In the dorsal horn of OA rats 3-wk following MIA, double labeling with anti
pERK1/2 (A-C) revealed colocalization with anti-NeuN/neuron (A), but not anti-GFAP/astrocyte (B) or anti-OX-42/microglia (C). Double labeling
with anti-p-p38 (D-F) revealed colocalization with anti-NeuN (D), but limited to a subpopulation of small-diameter neurons. Colocalization of anti
p-p38 in glial cells was not observed with anti-GFAP (E), but was observed with anti-OX-42 (F).
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Page 4 of 10pERK1/2 when immunohistochemically processed
immediately following grip force testing, whereas
PD98059-treated MIA-OA rats did not exhibit the same
significant increase (Figure 7B). Together, these results
suggest that MIA-induced nociceptive behavior, i.e.
reduced grip strength is associated with spinal pERK1/2
phosphorylation-activation.
Discussion
The use of intra-articular MIA as an animal model of OA
has been previously reported to display multiple compo-
nents of disease progression and symptoms akin to
human OA pathology [8-10]. However, demonstration of
biochemical changes involving nociceptive signaling in
this model are not as well established, in particular mar-
kers of central sensitization associated with chronic pain.
The present study examined the development and main-
tenance MAPK phosphorylation-activation in the dorsal
horn spinal cord as an index of central pain sensitization
in the MIA-OA model. While MIA-injection into the
hind limb joint reduced hind limb grip force asymptoti-
cally at all three time points tested (post injection week 1,
2, and 3), immunohistochemical evaluation of MAPK
activation revealed differential temporal characteristics
between pERK1/2 and phospho p38 MAPK. Specifically,
pERK1/2 immunoreactivity in dorsal horn of spinal cord,
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Figure 5 Spinal glial activation in MIA-OA rats. Microglia, but not astrocyte, activation was observed in the ipsilateral dorsal horn 3-wk
following MIA injection (Figure 5). In 3-wk MIA-treated rats, a significant increase in ipsilateral, but not contralateral, microglia expression was
observed in the spinal dorsal horn, as determined by OX-42 (CD11b) immunoassaying, when compared to naive controls (A). In contrast, 3-wk
MIA rats exhibited no differences in ipsilateral or contralateral astrocyte expression, as determined by GFAP immunoassaying, when compared to
naive controls (B). All data are represented as mean values (± S.E.M) of the percent of ipsilateral naïve control rats; * p < 0.05 vs. naïve controls
(Fisher’s PLSD post hoc analysis); n = 6/group.
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Page 5 of 10expressed in neurons, but not glia, was gradually
increased following MIA injection and reached a signifi-
cant level at post injection week 2 and 3 compared to
naïve control. In contrast, enhanced phosphorylation of
p38 MAPK, expressed primarily in microglia, was great-
est at post injection week 1 and steadily reduced toward
baseline thereafter. In addition, elevated MAPK phos-
phorylation was observed in the dorsal horn contralateral
to the MIA-injected paw, which was accompanied by
mechanical allodynia in the contralateral paw of 3-wk
MIA-treated rats. Finally, it was demonstrated that i.t.
administration of an ERK1/2 inhibitor in 3-wk MIA rats
produced antinociception (normalized grip force
s t r e n g t h )t h a tc o r r e l a t e dw i t ha t t e n u a t i o no fs p i n a l
pERK1/2 expression. Interestingly, spinal activation of
microglia, but not astroglia, was also observed in MIA-
treated rats.
It has been suggested that the early, transient synovial
inflammation observed in MIA-treated rats may be the
predominant cause of initial pain in MIA-OA rats,
whereas later pain may result from biomechanical forces
affecting the articular cartilage and subchondral bone
[7]. It is interesting to speculate that different MAPKs
may be involved in stages of OA disease progression,
consistent with the temporal-dependent and differential
profile of spinal ERK1/2 and p38 phosphorylation in
MIA-OA rats observed in the present studies. Although
the cellular mechanisms underlying chronic pain syn-
dromes are not well understood, there is accumulating
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Figure 6 Comparisons of MIA-induced contralateral paw
allodynia to spinal ERK phosphorylation. Mechanical allodynia,
measured as withdrawal threshold (***p < 0.001 vs. naïve control),
was observed on the contralateral paw 3-wk following MIA (A). In
the 3-wk MIA-treated rats, ERK phosphorylation was observed in
both ipsilateral and contralateral dorsal horn spinal when
immunohistochemically evaluated immediately following allodynia
testing (B). ERK1/2 phosphorylation data are represented as mean
values (± S.E.M) of the percent of ipsilateral naïve control rats; ** p
< 0.01 vs. naïve controls (Fisher’s PLSD post hoc analysis); n = 5-7/
group.
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Figure 7 Effects of MEK (ERK kinase) inhibitor PD98059 on
pERK1/2 immunoreactivity in spinal dorsal horns. Intrathecal
administration of PD98059 (10 μg) 30-min before nociceptive
behavior assessment attenuated the MIA-induced reduction of grip
force strength in 3-wk MIA rats (A). Grip force strength was
expressed as CFmax/kg body weight; *p < 0.05, **p < 0.01 vs. naïve
controls, # p < 0.05 vs. vehicle alone treated MIA rat; n = 6/group.
MIA-OA vehicle-i.t. controls rats displayed a significant increase in
spinal pERK1/2 when immunohistochemically processed
immediately following grip force testing, whereas PD98059-treated
MIA-OA rats did not exhibit the same significant increase (B). ERK
phosphorylation data are represented as mean values (± S.E.M) of
the percent of ipsilateral naïve control rats; ** p < 0.01 vs. naïve
controls (Fisher’s PLSD post hoc analysis); n = 6/group.
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Page 6 of 10evidence supporting the role of plastic changes involving
expression and function of ion channels, receptors and
neurotransmitter-peptides in sensory systems responsi-
ble for pain transmission (e.g. spinal cord). Among the
list of signaling molecules that may regulate the plasti-
city associated with chronic pain, MAPKs that include
ERK and p38 have recently generated much interest
[17,20]. As described here, the changes in MAPK phos-
phorylation-activation observed in MIA-injected rats, a
novel finding, support a role of ERK1/2 and p38 in the
development and maintenance of pain associated with
OA pathology.
Although we are not aware of prior reports examining
MAPK expression in MIA-treated rats, or other experi-
mental models of OA, neuropathic pain models invol-
ving spinal nerve injury have been well characterized for
changes in MAPK phosphorylation involving central and
peripheral sensitization. Specifically, activation of spinal
ERK1/2 and p38 is induced following peripheral nerve
injury in experimental models that includes: L5 spinal
nerve ligation (SNL) and chronic constriction injury
(CCI) of the sciatic nerve [21-25]. In general, studies
conducted in nerve injury models have demonstrated
that pERK1/2 activation occurs rapidly and transiently
(10 min to 6 hr following nerve injury) in spinal dorsal
horn neurons, with subsequent activation in glia cells,
both microglia and astrocytes, two to 28 days later. In
contrast, p38 induction appears to only occur in micro-
glia, observed one to 14 days following nerve injury.
In the present studies, the diverse temporal profiles of
spinal ERK1/2 and p38activation observed in MIA rats
may reflect differential MAPK expression by distinct cell
types, i.e. neurons and glia, as seen in nerve injury mod-
els. Specifically, expression of pERK1/2 was only
observed in dorsal horn neurons at 3-wk following MIA,
a time point where nociceptive behavior is well estab-
lished and used in pharmacological antinociceptive test-
ing [13]. In contrast, expression of p-p38 was primarily
observed in microglia, but not astrocytes. However, a
subpopulation of small diameter neurons in the superfi-
cial lamina, also expressed p-p38. It is interesting to
note that microglia, but not astroglial, activation was
observed in 3-wk MIA-treated rats, consistent with glial
p-p38 expression restricted to microglia. Taken together,
while there appears to be distinct temporal and bio-
chemical discrepancies between our findings and pain
models involving peripheral nerve injury, the pathogenic
differences that likely exist between joint and nerve
injury may explain these variations.
It is noteworthy that the contralateral spinal dorsal
horn also showed a substantial increase in MAPK phos-
phorylation-activation following MIA injection. More-
over, mechanical allodynia was observed in the
contralateral limb, demonstrating the parallel increase in
MAPK activity has functional, i.e. pronociceptive conse-
quences. In contrast, spinal MAPK activation reported
in nerve injury models is primarily seen in the dorsal
horn ipsilateral, but not contralateral, to injury [17].
Interestingly, there have been demonstrations of periph-
eral-nerve lesions that affect contralateral nonlesioned
structures involving signaling via the system of commis-
sural interneurons present in spinal cord and brainstem
[26]. The excitatory communications between both sides
of the spinal cord have been also demonstrated using
electrophysiological techniques; Fitzgrald reported
approximately 20% of cells in the substantia gelatinosa
of the lumbar spinal cords showed a strong excitatory
activation upon tetanic stimulation of the contra lateral
sciatic nerve [27]. To our knowledge, the present data is
the first demonstration of nociceptive-induced cellular
signaling from ipsi to contralateral spinal dorsal horns
following MIA injection, a finding that has not been
observed in neuropathic peripheral nerve injury models
such as SNL and CCI. However, Gao and colleagues
recently demonstrated increased bilateral spinal cord
expression of the MAPK JNK in the complete Freund’s
adjuvant model of persistent inflammatory pain [28].
Taken together, results of these studies and those pre-
sented here may suggest that the MIA-OA model share
biochemical signaling properties of both neuropathic
and inflammatory pain states.
It was observed that increased spinal ERK1/2 phos-
phorylation in 3-wk MIA-OA rats was blocked by the
MEK inhibitor PD98059 when examined 30 min follow-
ing acute intrathecal administration, as would be
expected. Moreover, PD98059 treatment partially
blocked the pain behavior, reduced grip force strength,
observed in MIA-OA rats, supporting the potential
involvement in part of ERK1/2 phosphorylation in the
dorsal horn spinal cord in mediating nociceptive-
induced central sensitization associated with this model
of OA. Consistent with our findings, the ability of
PD98059 to produce antinociception has been pre-
viously demonstrated in various pain models including
formalin [29], complete Freund’s adjuvant-induced
inflammation [30] and CCI [31].
Conclusions
Evaluation of biochemical pathways associated with central
sensitization in animal models of OA has been lacking
compared to neuropathic pain models involving peripheral
nerve injury. Our current study demonstrates that activa-
tion of ERK1/2 and p38 MAPKs in the dorsal horn spinal
cord is involved in nociceptive behaviors observed in the
MIA-OA model. Furthermore, the ERK and p38 MAPK
activation observed, which occurs primarily in neurons
and microglia, respectively, displayed different temporal
characteristics following MIA injection, suggesting possibly
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tenance of central pain sensitization. Taken together, these
findings provide improved understanding of the biochem-
ical relationship of MAPK activation and pain-induced cen-
tral sensitization in the rat MIA-OA model, and may serve
as a mechanistic tool for evaluating novel analgesic agents
for the treatment of chronic pain associated with OA.
Methods
Animals
Adult male Sprague-Dawley rats (250-300 g, n = 6/
group) were used in experiments according to the inter-
nal Institutional Animal Care and Use Committee
guidelines (Charles River Laboratories, Wilmington,
MA). The animals were housed in Association for
Assessment and Accreditation of Laboratory Animal
Care (AAALAC) approved facilities at Abbott Labora-
tories in a temperature-regulated environment under a
controlled 12-h light-dark cycle, with lights on at 6:00 a.
m. Food and water were available ad libitum at all times
except during testing.
MIA injection: Osteoarthritic model of pain
Unilateral knee joint osteoarthritis was induced by a sin-
gle intra articular (i.a.) injection of sodium monoiodoace-
tate (Sigma, St. Louis, MO) (MIA, 3 mg in 0.05 ml sterile
isotonic saline) into the right knee joint cavity under
light halothane (Halocarbon Laboratories, River Edge,
NJ). Following injection, the animals were allowed to
recover from the effects of anesthesia (usually 5-10 min)
before returning them to their home cages.
To evaluate antinociceptive behavior and MAPK acti-
vation following MIA injection, separate groups of body
weight matched Sprague-Dawley rats were injected with
MIA on Day 0 (post MIA-injection week 3 group), Day 7
(post MIA-injection week 2 group), or Day 14 (post
MIA-injection week 1 group). On Day 21, all MIA-
i n j e c t e da n i m a l sa sw e l la so n eg r o u po fn a ï v ec o n t r o l
animals were subjected to a grip force test. Twenty four
hours later, all animals were perfused as described below.
MIA-induced nociceptive behavior at the contra lat-
eral side was examined in a separate experiment. One
group of animals was injected with MIA on Day 0 and
allowed to recover for 21 days. On Day 21, the MIA-
injected animals and one group of naïve control animals
received grip force tests. On Day 22, a von Frey test was
given to access contra lateral hind paw responses of all
animals. Following 24 hour recovery, all animals were
perfused, and spinal cords were harvested.
Intrathecal catheterization and injection of PD98059
The effects of a MEK inhibitor on MIA-induced pain
behavior and pERK1/2 expression were evaluated. On
the post MIA-injection Day 14, naive control animals, as
well as MIA-injected animals received i.t. catheterization
as previously described [32]. Briefly, rats were placed
under isoflurane anesthesia and mounted onto a stereo-
taxic instrument using blunt ear bars, which held the
animal’s head firmly. An incision was made vertically
from the dorsal surface of the occipital bone to the base
of the skull (2 cm). Tissue was then displaced using a
blunt probe so that the alanto-occipital membrane at
the base of the skull was clearly seen. An intrathecal
PE-10 catheter was inserted through the atlanto-occipi-
t a lm e m b r a n ev i aas m a l lh o l ei nt h ec i s t e r n am a g n u m .
The catheter was then advanced 8.5 cm caudally such
that the tip ended in the spinal subarachnoid space
around the lumbar enlargement (L4-L6). The catheter
was then secured to the musculature at the incision site.
The incision was closed with surgical wound clips. The
catheter was filled with sterile physiological saline and
the ends of the catheter were heat-sealed. Animals with
catheters were allowed 1 week of recovery from surgery
before behavioral testing. The catheter was subsequently
flushed with 10 μl of sterile water to maintain the
patency.
On post MIA injection Day 21 (post IT catheterization
Day 7), the animals were divided into four groups, one
group of MIA-injected animals and one naïve control
group animals were injected intrathecally with 10 μg
(2 mg/10 ml/1 min/rat) of the MEK (ERK kinase) inhi-
bitor PD98059 dissolved in a vehicle of 10% DMSO/
HBC (dimethyl sulfoxide/2-hydroxypropyl-b-c y c l o d e x -
trin), while remaining groups were injected with the
vehicle alone. Thirty minutes after i.t. injection, the ani-
mals were subjected to grip force test. Immediately after
the behavioral test, the animals were perfused and their
spinal cords were harvested.
Behavioral testing: Hind Limb Grip Force test
Measurements of peak hind limb grip force were con-
ducted by recording the maximum compressive force
exerted on the hind limb strain gauge setup, in a com-
mercially available grip force measurement system
(Columbus Instruments, Columbus, OH). During test-
ing, each rat was gently restrained by grasping around
its rib cage and then allowed to grasp the wire mesh
frame (10-12 cm2) attached to the strain gauge. The
experimenter then moved the animal in a rostral-to-
caudal direction until the grip was broken. Each rat was
sequentially tested twice at an approximately 2 min
interval to obtain a raw mean grip force (CFmax). These
raw mean grip force data were in turn converted to a
maximum hind limb compressive force (CFmax) (gram
force)/kg body weight for each animal. A group of age-
matched naïve animals was added and the data obtained
from MIA-injected animals was compared to that of the
naïve control group.
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Mechanical threshold was measured using calibrated
von Frey monofilaments (Stoelting, Wood Dale, IL). Paw
withdrawal threshold (PWT) was determined by increas-
i n ga n dd e c r e a s i n gs t i m u l u si ntensity, and estimated
using the Dixon’s up-down method [33]. Rats were
placed individually in inverted plastic containers (20 ×
12.5 × 20 cm) on top of a suspended wire mesh with a
1c m
2 grid to provide access to the ventral side of the
hind paws. Rats were acclimated to the chambers for
20 min prior to testing. Monofilaments were presented
perpendicularly to the plantar surface of the selected hind
paw, and then held in this position for approximately 8
sec with enough force to cause a slight bend in the fila-
ment. Positive responses included an abrupt withdrawal of
the hind paw from the stimulus, or flinching behavior
immediately following removal of the stimulus. A 50%
withdrawal threshold was determined using an up-down
p r o c e d u r e[ 3 4 ] .T h es t r e n g t h of the maximum filament
used for von Frey testing was 15 g. A percent maximal
possible effect (% MPE) of testing compound was calcu-
lated according to the formula: ([compound - treated
threshold] - [vehicle - treated threshold])/([maximum
threshold] - [vehicle-treated threshold]) × 100%, where the
maximum threshold was equal to 15 g.
Perfusion and tissue harvest
The animals were deeply anesthetized with CO2 and
perfused through the aorta with buffered saline (3 min,
25 ml/min) followed by 10% formalin (12 min, 30 ml/min).
The spinal cords were extracted using hydraulic pressure
and post-fixed in 10% formalin and stored in 20% sucrose
PBS for overnight before sectioning.
Immunohistochemistry of free-floating spinal cord
sections
After overnight incubation in 20% sucrose-PBS, the
lumbar regions of spinal cords containing L3 to L5 were
cut on a cryostat (40 μm coronal sections). Prior to sec-
tioning, a knife cut was made through the ventral horn
of spinal cords contra lateral to injection site for site
specific evaluation of the data. The lumbar sections
were immunostained in a free floating system for either
anti-phospho p44/42 MAP Kinase (pERK 1/2) antibody
(rabbit IgG, 1:700, Cell Signaling #9101), anti-phospho
p38 MAP Kinase (Thr180/Tyr182) antibody (rabbit IgG,
1:1000, Cell Signaling # 9211L), anti-CD11b (OX-42)
antibody (mouse IgG, 1:500, AbD Serotec), anti-GFAP
antibody (mouse IgG, 1:1000, Millipore) using a three-
step ABC-peroxidase technique beginning with a 30 min
incubation with H2O2/PBS-Triton solution. Following
PBS washes (3X); the sections were incubated with
blocking serum (20 min) followed by the primary anti-
body for an overnight incubation. Twenty hrs later, the
sections were washed with PBS (3x), and incubated for
1 hr with a secondary anti-rabbit IgG polyclonal anti-
body (goat IgG, 1:200; Vector Labs). Immunoreactivity
was developed by an ABC (avidin-biotin)-peroxidase
reaction using diaminobenzadine (DAB) as a chromo-
genic substrate. Sections were mounted, cover-slipped,
and digitally photographed at 10× (Olympus BX-51
scope with F-View camera) with a shading correction to
compensate for uneven illumination. Staining was quan-
tified using an image analysis system (Olympus Micro-
Suite Five) by measuring number of cells with
homogeneous staining of a given antibody in laminae
I-III of the spinal dorsal horns.
Double-labeling to determine the cellular phenotype of
pERK1/2 and p-p38 expressing cells was carried out by
antibody co-incubations of either anti-pERK1/2 or anti-
p-p38 with the neuronal marker anti-NeuN, microglia
marker anti-OX-42, or astroglia marker anti-GFAP. Spe-
cifically, 20 μm free floating lumbar spinal cord sections
were blocked for 1-hr in 10% normal donkey serum, at
room temperature. Sections were next coincubated with
primary antiseras overnight at 4°C that consisted of anti-
pERK (rabbit IgG, 1:500, Cell Signaling Technology) with
either anti-NeuN (mouse IgG, 1:500, Millipore), anti-
GFAP (mouse IgG, 1:1000, Millipore), or anti-OX-42
(mouse IgG, 1:500, AbD Serotec). Similar coincuba-
tions using the three cellular antibody markers were
also made with anti-p-p38 (rabbit IgG, 1:500, Cell Sig-
naling Technology). Following primary coincubations,
sections were washed (3X, 2-hrs) in PBS and co-incu-
bated with secondary fluorescence dye antibodies con-
sisting of donkey-anti-rabbit Cy3 (1:500, Jackson Labs)
and donkey anti-mouse Cy2 (1:500, Jackson Lab) for
1-hr at room temperature. Next, sections were washed
(2X, 15 min) at room temperature, followed by an
overnight wash in PBS at 4°C. Sections were then
mounted on slides, dehydrated through series of
ETOH (70, 95, 95, 100, 100%) for 2-3 minutes, then
cleared in xylene and coverslipped with DPX. Cy2
(green, ~492 nm excitation, ~510 nm emission) and
Cy3 (red, ~550 nm excitation, ~570 nm emission)
fluorescence microscopy was conducted with an Olym-
pus BX51 fluorescence microscope.
Statistics
Data were converted to percent change of ipsilateral
naïve control and analyzed using one-way or two-way
analysis of variance (ANOVA) followed by Fisher’sp r o -
tected least squares difference (PLSD) post-hoc analysis.
A p-value < 0.05 was considered statistically significant.
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